Clearmind Medicine Inc. Common Shares logo

Clearmind Medicine Inc. Common Shares(CMND)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL
1-STAR RATING
PASS
LAST CLOSE
$3.06
11/18/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for CMND

11/18/2026: CMND (1-star) is currently NOT-A-BUY. Pass it for now.

Clearmind Medicine Inc. is a clinical-stage biopharmaceutical company focused on developing non-hallucinogenic, psychedelic-derived neuroplastogen therapeutics for conditions like alcohol use disorder. Its primary growth catalyst rests on advancing its lead candidate, CMND-100, through early-stage clinical trials while maintaining a protected intellectual property portfolio. However, the company faces substantial risks, including a pre-revenue operating status, ongoing net losses, and high clinical development uncertainty. This stock suits speculative growth investors comfortable with high volatility and micro-cap biotech risk, while key developments to monitor include upcoming clinical trial data readouts and capital-raising updates.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorWeak fitThe company lacks commercial revenue growth, relying instead on high-risk binary clinical trial milestones.
Momentum investorStrong fit while signal remains positiveMicro-cap clinical stocks can experience sharp, short-term speculative rallies around clinical trial updates or regulatory news.
Value investorWeak fitTraditional value metrics do not apply given persistent net losses and lack of earnings or cash-generative operations.
Dividend investorWeak fitThe company pays no dividends and channels all available financial resources into drug development.
Low-risk investorWeak fitHigh clinical, regulatory, and dilution risks make this equity unsuitable for risk-averse portfolios.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighMicro-cap clinical biotech shares frequently display extreme price swings based on news flow and market sentiment.
Valuation riskHighValuations are highly speculative due to the absence of traditional revenue or earnings streams.
Competition risk (psychedelic biotech competition)Medium / highNumerous well-capitalized biotech firms are pursuing competing treatments for central nervous system and addiction disorders.
Business qualityHighThe business model remains unproven commercially until a therapeutic compound successfully achieves regulatory approval.
Dividend incomeLow / noneNo cash returns are distributed to shareholders via dividends.
Execution riskHighClinical trial success, regulatory compliance, and future funding execution are critical operational hurdles.

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 1.54M USD
Price to earnings Ratio -
1Y Target Price -
Price to earnings Ratio -
1Y Target Price -
Volume (30-day avg) 8.5K shares
Beta 0.51
52 Weeks Range 3.03 - 716.80
Updated Date 11/18/2026
52 Weeks Range 3.03 - 716.80
Updated Date 11/18/2026
Dividends yield (FY) -
Basic EPS (TTM) -461.2

Sector & Industry Intelligence

Sector

Healthcare

Constructive
Sentiment
Strong Bullish
Momentum
BUY Breadth Improving
BUY participation
62.3%
Active BUY / eligible
66 / 106
30-Day BUY Count Change
+23
Market state
Strong Bullish

More qualifying stocks are receiving or maintaining BUY advisories, indicating improving market participation.

Industry

Biotechnology

BUY participation
43.6%
Active BUY / eligible
17 / 39
30-Day BUY Count Change
+10

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Steep Decline
PRICE PATH

Steep Decline

The stock price has dropped sharply with strong downward pressure.

Extreme Price Shocks
PRICE STABILITY

Extreme Price Shocks

The stock has experienced exceptionally large and disruptive price movements during the period.

Analysis of Past Performance

Type Stock
Historic Profit -31.55%
Avg. Invested days 24
Today’s Advisory PASS
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 1.0
Stock Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/18/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
CMND receives a 2-star rating, reflecting soft or weak scores across the available pillars. The rating is constrained by weak unit economics, soft analyst coverage, and weak price momentum.

Company Fundamentals

★★★★★
CMND has moderate overall fundamentals (3 stars), with moderate financial health, moderate growth momentum, and moderate ownership. In FY2025 versus FY2024, solid earnings growth (+26.6%) is partially offset by soft cash generation (FCF margin 0.0%), slightly negative revenue growth (+0.0%), soft profitability (net margin 0.0%).

Financial Health Rating

★★★★★
CMND's financial health is supported by strong efficiency, including operating-expense and cost-of-revenue discipline (opex 0.0% of revenue). Profitability is weak (1 stars), which helps explain the 3-star overall score.

Growth Momentum Score

★★★★★
Free-cash-flow growth is CMND's strongest growth driver at +30.0% FY2025 versus FY2024 (solid, 4 stars). By comparison, earnings growth (+26.6%, solid) is also solid, while revenue growth (+0.0%, slightly negative) holds the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 1.5% (soft) and 77.6% of outstanding shares are publicly tradable (solid). Insider ownership of 5.02% supports management-shareholder alignment.

Top 5 Institutional Investors

HRT FINANCIAL LLC 0.87%
Citadel Advisors Llc 0.29%
AdvisorShares Investments, LLC 0.03%
Morgan Stanley - Brokerage Accounts 0.02%
Royal Bank of Canada 0.01%

Unit Economics (Per $1K Revenue)

★★★★★
CMND generates approximately $-0 of gross profit, $-0 of operating income, and $-0 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Weak margins explain the 1-star rating, with weak cash conversion and strong capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: -1.86% (Tax Credit)

Quantitative Style Profile

★★★★★
CMND has a liquid, relatively low-volatility profile. Weak momentum is the primary drawback.

Style Classification

Quality Focused

Low VolatilitySmall / Mid Cap RiskHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
Therapeutic Pipeline DevelopmentFuture commercialization rights, licensing fees, or product sales derived from proprietary neuroplastogen compounds like CMND-100.The company currently does not generate commercial revenue and operates as a pre-revenue clinical research firm.

Valuation

Trailing PE -
Forward PE -
Enterprise Value -12.38M
Price to Sales(TTM) -
Enterprise Value -12.38M
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA -0.79
Shares Outstanding 507.40K
Shares Floating 393.87K
Shares Outstanding 507.40K
Shares Floating 393.87K
Percent Insiders 5.02
Percent Institutions 1.5

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.